CNTA

Centessa Pharmaceuticals
CNTA

$8.27
0.96%
 

About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Employees: 75

0
Funds holding %
of 6,665 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

367% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 6

254% more call options, than puts

Call options by funds: $200K | Put options by funds: $56.5K

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

150% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 5 (+3) [Q1 2024]

48% more capital invested

Capital invested by funds: $567M [Q4 2023] → $841M (+$273M) [Q1 2024]

19% more funds holding

Funds holding: 58 [Q4 2023] → 69 (+11) [Q1 2024]

3.19% more ownership

Funds ownership: 73.01% [Q4 2023] → 76.2% (+3.19%) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$15
81%
upside
Avg. target
$15
81%
upside
High target
$15
81%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
BMO Capital
Kostas Biliouris
81%upside
$15
Outperform
Maintained
1 Apr 2024

Financial journalist opinion